AttgeNO (private company)
See something wrong or missing? Let us know
Offices:Stockholm
Industry:BiotechHealth servicesPharma
Business model:B2B
AttgeNO is working on the development of new blood vessel-inducing drugs. Supernitro (PDNO) is a new patented drug candidate for the treatment of acute life threatening high blood pressure in the lung, which may occur in conjunction with cardiac surgery and fatal outcome.
Investors:
we tracked 2 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 3.44M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to AttgeNO
Name | Criteria | |
---|---|---|
![]() |
AbolerIS Pharma
63%
|
|
![]() |
Athera
63%
|
|
![]() |
Oui
63%
|
|
![]() |
Synklino
63%
|
|
![]() |
PEP-Therapy
63%
|
|
![]() |
DelSiTech
60%
|
|
![]() |
Ilya Pharma
60%
|
|
![]() |
Abarceo Pharma
60%
|
|
![]() |
Pila Pharma
60%
|
|
![]() |
Betagenon
60%
|
|